Table 1.
Baseline characteristics of the patients
| ALB tertiles | TI group (0.00–2.20 g/dl) |
T2 group (2.30–2.70 g/dl) |
T3 group (2.80–5.90 g/dl) |
P value |
|---|---|---|---|---|
| N (794) | 218 | 286 | 290 | |
| ALB | 1.92 ± 0.32 | 2.50 ± 0.14 | 3.17 ± 0.39 | < 0.001 |
| Time to death = 28 days | 28.00 (3.00–28.00) | 28.00 (4.00–28.00) | 28.00 (7.00–28.00) | 0.024 |
| Time to death = 90 days | 3.00 (1.00–29.69) | 5.80 (1.00–58.96) | 14.40 (1.00–90.00) | < 0.001 |
| Age (years) | 65.00 ± 12.85 | 63.72 ± 14.49 | 62.49 ± 14.59 | 0.137 |
| K (mmol/L) | 4.76 ± 1.15 | 4.59 ± 0.99 | 4.77 ± 1.12 | 0.098 |
| HCO3 (mmol/L) | 15.71 ± 5.18 | 17.10 ± 5.67 | 17.73 ± 5.76 | < 0.001 |
| P (mg/dL) | 5.53 ± 2.26 | 5.47 ± 2.15 | 5.90 ± 2.45 | 0.067 |
| aCCI score | 2.00 (1.00–5.00) | 3.00 (2.00–5.00) | 3.00 (1.25–4.00) | 0.155 |
| BMI (kg/m2) | 23.36 ± 4.48 | 23.39 ± 4.34 | 23.89 ± 4.54 | 0.309 |
| SBP (mmHg) | 110.44 ± 20.62 | 112.21 ± 21.71 | 111.71 ± 20.50 | 0.632 |
| DBP (mmHg) | 61.00 ± 13.91 | 61.05 ± 14.70 | 60.28 ± 13.79 | 0.774 |
| MAP (mmHg) | 77.42 ± 14.02 | 77.76 ± 15.58 | 77.23 ± 14.62 | 0.909 |
| WBC (uL) | 10,690.00 (5130.00–18,960.00) | 11,070.00 (6355.00–18,285.00) | 12,060.00 (8170.00–18,740.00) | 0.171 |
| HGB (g/dL) | 9.23 ± 2.06 | 9.73 ± 1.98 | 10.03 ± 2.37 | < 0.001 |
| BUN (mg/dL) | 55.00 (36.00–78.00) | 49.00 (35.00–74.00) | 48.00 (34.00–71.00) | 0.162 |
| Cr (mg/dL) | 2.26 (1.59–3.16) | 2.42 (1.67–3.39) | 2.34 (1.66–3.36) | 0.358 |
| CRP (mg/L) | 89.60 (20.10–199.50) | 73.25 (20.55–176.70) | 46.90 (15.00–133.50) | 0.011 |
| GFR (ml/min/1.73 m2) | 27.05 (18.27–39.55) | 26.45 (17.62–38.98) | 26.30 (16.17–38.60) | 0.547 |
| UO (mL) | 25.00 (4.25–100.00) | 30.00 (5.00–96.25) | 40.00 (10.00–100.00) | 0.139 |
| APACHE-II score | 28.37 ± 7.63 | 27.46 ± 7.64 | 26.60 ± 8.48 | 0.047 |
| SOFA score | 12.26 ± 3.38 | 12.16 ± 3.45 | 11.64 ± 3.73 | 0.09 |
| CRRT dose (mL/kg) | 36.99 ± 5.01 | 36.62 ± 4.85 | 36.57 ± 4.39 | 0.579 |
| Sex | 0.187 | |||
| Male | 132 (60.55%) | 189 (66.08%) | 171 (58.97%) | |
| Female | 86 (39.45%) | 97 (33.92%) | 119 (41.03%) | |
| MV | 0.049 | |||
| No | 36 (16.51%) | 57 (19.93%) | 73 (25.26%) | |
| Yes | 182 (83.49%) | 229 (80.07%) | 216 (74.74%) | |
| Indications for CRRT | 0.326 | |||
| Volume overload | 22 (10.09%) | 35 (12.24%) | 45 (15.52%) | |
| metabolic acidosis | 49 (22.48%) | 73 (25.52%) | 61 (21.03%) | |
| hyperkalemia | 14 (6.42%) | 8 (2.80%) | 17 (5.86%) | |
| uremia | 23 (10.55%) | 33 (11.54%) | 25 (8.62%) | |
| oliguria | 53 (24.31%) | 77 (26.92%) | 75 (25.86%) | |
| others | 57 (26.15%) | 60 (20.98%) | 67 (23.10%) | |
| AKIN stage | 0.983 | |||
| stage II | 59 (27.06%) | 76 (26.57%) | 79 (27.24%) | |
| stage III | 159 (72.94%) | 210 (73.43%) | 211 (72.76%) |